Navigation Links
Hyderabad To Have Asia’s First Catheter Making Uni

Hyderabad capital of Andhra Pradesh is set to house Asia's first catheter manufacturing facility, which will not only bring down the cost of catheter// based disposables but could also become an outsourcing hub for multinational companies.

Relisys Medical Devices Limited, a seven-year old company, Tuesday announced that the facility would be ready by December. Trial production is slated to begin by January next year.

The Rs.80 million facility, coming up at Manglapalli village in neighbouring Ranga Reddy district, will have the capacity to produce half a million catheter-based products annually.

To be developed as per US Food and Drug Administration (FDA) norms, it will produce 150,000 to 200,000 diagnostic catheters and 60,000 to 70,000 interventional catheters, used to pass stents to cardiac arteries.

N. Krishna Reddy, cardiologist and chairperson of Relisys, told reporters that Andhra Bank had come forward to extend a term loan of Rs.45 million for the facility.

He later told IANS that the facility would be a big boost to development of medical devices in a country, which presently produces only IV sets. "From the lowest level we are jumping to the sixth level," he said.

Krishna Reddy hoped the facility would cut the prices of catheters by 50 to 70 percent. India imports catheters at prices ranging from Rs.400 to Rs.3,000.

"This facility can not only cater to the region but also become an outsourcing hub for MNCs," he said.

The company also announced the launching of international multi-centre clinical trials of the new version of drug eluting cobalt-chromium stent coated with porous carbon-carbon nano-matrix.

Clinical trials would be conducted at nine centres in India as well as in Brazil, South Korea, Italy and Japan. The company has entered into a worldwide licensing agreement with Blue Membranes GmbH, Germany, for carbon-based drug delivery platform.

The use of porous carbon-carbon nano particle coating will eliminate the use of polymer based platform, thus completely reducing tissue inflammation and reaction (in cardiac arteries).

"Blue-Membranes will enforce the collaboration with Relisys that enables us to exploit our drug-delivery technology. We also aim to integrate manufacturing capabilities of Relisys to provide high quality manufacturing services for integrated solutions," said Soheil Asgari, CEO of Blue-Membranes.

Animal trials of this version of advanced drug eluting stent were recently completed at the Cardiovascular Research Institute, Washington.

The company had earlier completed clinical trials for its first generation drug eluting stent at All India Institute of Medical Sciences, New Delhi, Military Hospital, Pune, and Care Hospital, Hyderabad. More than 500 stents have been used since evaluation was completed six months ago.

Source: IANS


'"/>




Related medicine news :

1. Hyderabad Firm To Manufacture Tamiflu In India
2. Biotechnology Initiatives Planned In Hyderabad
3. US Consulate to Start Hyderabad Operations Next Year
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. First human clone is near
7. First Artificial Heart patient has Major setback
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. WHO Declares Vietnam First Country to Control SARS
10. Russia Reports First SARS Case
11. Hope for First New Melanoma Treatment in Decades
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: